2018 Congress of the Mexican Association of Oncological Urology

Biomarkers in Immunotherapy for Bladder Cancer

Acapulco, GRO, Mexico (UroToday.com) Clinical judgment/data is the key to predicting the response of intravesical BCG, actually, no biomarker can supersede our clinical data.  Ashish Kamat, MD explains four biomarkers we could use to identify response to immunotherapy: PD-L1 status, molecular subtyping, tumor mutational burden and immune gene expression profiling.

UroToday SMEO2018 Biomarkers in Immunotherapy for Bladder Cancer 1

The PD-L1 expression (prognostic factor) is seen in approximately 20-30% of specimens and it’s associated with the increased pathologic stage, increased all-cause mortality and more aggressive disease. Durvalumab correlates with PD-L1 high expression with greater efficacy (High PD-L1, objective response rate of 31% VS 5.1% of low/negative PD-L1, but efficacy is still observed). Atezolizumab and pembrolizumab had no impact of PD-L1 status on overall survival.

UroToday SMEO2018 Biomarkers in Immunotherapy for Bladder Cancer 2

In the IMvigor 210 trial (atezolizumab) was found that basal clusters had the highest prevalence of IC 2/3 PD-L1 (60 VS 23%) and TC 2/3(39 VS 8%), but the highest response was in luminal cluster II subtype (ORR=34%, p=0.0017).

The tumor mutational burden (neoantigen burden) is associated with a greater likelihood of durable responses to immune checkpoint blockade. Neoantigen burden predicts response more robustly than PD-L1 and presence of TILs. IMvigor 210: cohort II found a higher mutational load in responding vs non-responding patients (12.4 VS 6.4 per megabase, p<0.0001).

Multiparameter immune gene expression profiling in the Checkmate 275 study (nivolumab) found IFN-γ signature correlated with better response to nivolumab (high IFN-γ signature: CR/Prin 20/59 patients; medium or low IFN-γ signature: CR/PR in 18/118 patients; p=0.0003).

Kamat concluded that PD-L1 positivity inconsistently enriches for clinical benefit, TCGA and other subtypes have varied associations, tumor mutational burden correlates with response and immune gene expression profiles studies still ongoing for findings.

Presented by: Ashish M. Kamat, MD, Professor of Urologic Oncology, MD Anderson Cancer Center, Houston, TX

Written by: Eduardo Gonzalez-Cuenca, MD, Urology Resident, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City and Ashish M. Kamat, MD, Professor of Urologic Oncology, MD Anderson Cancer Center, Houston, TX at the 2018 Congreso de la Asociación Mexicana de Urología Oncológica – July 25-28, 2018, Acapulco, GRO México

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.